全文获取类型
收费全文 | 14893篇 |
免费 | 1318篇 |
国内免费 | 298篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 116篇 |
妇产科学 | 74篇 |
基础医学 | 1352篇 |
口腔科学 | 2563篇 |
临床医学 | 1972篇 |
内科学 | 2569篇 |
皮肤病学 | 25篇 |
神经病学 | 1065篇 |
特种医学 | 877篇 |
外科学 | 1346篇 |
综合类 | 1106篇 |
一般理论 | 1篇 |
预防医学 | 1170篇 |
眼科学 | 79篇 |
药学 | 1093篇 |
6篇 | |
中国医学 | 625篇 |
肿瘤学 | 398篇 |
出版年
2024年 | 60篇 |
2023年 | 374篇 |
2022年 | 1164篇 |
2021年 | 1281篇 |
2020年 | 742篇 |
2019年 | 651篇 |
2018年 | 676篇 |
2017年 | 573篇 |
2016年 | 507篇 |
2015年 | 574篇 |
2014年 | 953篇 |
2013年 | 1080篇 |
2012年 | 760篇 |
2011年 | 938篇 |
2010年 | 681篇 |
2009年 | 641篇 |
2008年 | 665篇 |
2007年 | 594篇 |
2006年 | 481篇 |
2005年 | 381篇 |
2004年 | 325篇 |
2003年 | 316篇 |
2002年 | 280篇 |
2001年 | 221篇 |
2000年 | 145篇 |
1999年 | 155篇 |
1998年 | 150篇 |
1997年 | 126篇 |
1996年 | 148篇 |
1995年 | 105篇 |
1994年 | 96篇 |
1993年 | 86篇 |
1992年 | 71篇 |
1991年 | 67篇 |
1990年 | 59篇 |
1989年 | 47篇 |
1988年 | 46篇 |
1987年 | 41篇 |
1986年 | 33篇 |
1985年 | 29篇 |
1984年 | 45篇 |
1983年 | 19篇 |
1982年 | 21篇 |
1981年 | 18篇 |
1980年 | 17篇 |
1979年 | 12篇 |
1978年 | 14篇 |
1977年 | 9篇 |
1976年 | 12篇 |
1974年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
3.
4.
《Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society》2020,28(11):1412-1426
5.
6.
7.
M.A. Mashrah T.A. Aldhohrah A. Abdelrehem Moustafa H.M. Al-Sharani A. Alrmali L. Wang 《International journal of oral and maxillofacial surgery》2021,50(1):21-31
Donor site morbidity following radial forearm flap (RFF) harvest remains a controversial issue. The aim of this meta-analysis was to answer the question “Are the range of wrist movements (range of motion, ROM) and hand strength affected after RFF harvesting?” The PubMed, Embase, Scopus, and Cochrane Library electronic databases were systematically searched (to December 2019). Self-controlled studies evaluating hand biomechanics after RFF harvest were included. Weighted mean differences with 95% confidence intervals were calculated using the random-effects model. The outcome variables were ROM, forearm movements, grip, and pinch strengths. Thirteen studies involving a total of 335 patients were included. With the exception of grip strength and supination, which showed statistically significant reductions of about 2.40 kg and 2.86° (P < 0.05), all other ROM, forearm movements, and pinch strengths showed an insignificant difference when the operated hand was compared to the non-operated hand (P > 0.05). Regression analysis showed that the method of donor site closure and size of the donor site defect had an insignificant impact on hand biomechanics. This study confirms the lack of discernible biomechanical morbidity after RFF transfer. The minimal reduction in hand biomechanics after RFF is considered to be clinically negligible. 相似文献
8.
9.
《Clinical gastroenterology and hepatology》2022,20(8):1776-1783.e4
- Download : Download high-res image (187KB)
- Download : Download full-size image
10.
《Clinical therapeutics》2019,41(5):836-847
PurposeA role for the immune system in causing myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is long suspected, but few studies have looked for specific autoantibodies that might contribute to the symptoms. Our aim was to look for evidence of antibodies to neuronal proteins in patients with ME/CSF.MethodsSera samples from 50 patients and 50 healthy individuals were sent coded to the Neuroimmunology Laboratory in Oxford. Screening for antibody binding to neuronal tissue was performed on brain tissue and neuronal cultures. Specific serum antibodies were assessed by antigen-specific cell-based assays and radioimmunoassays. After antibody testing, the associations between seropositive status and clinical data were investigated.FindingsOverall, 8 patients and 11 participants were found to have some serum immunoreactivity toward neuronal or neuromuscular junction proteins, but only 1 patient and 2 participants had specific serum antibodies. Nevertheless, seropositive status in patients with ME was associated with shorter duration since onset and a more severe disease.ImplicationsThe results indicate no overall increased frequency of antibodies to neuronal proteins in ME/CSF and no evidence of a specific antibody that might be causative or contribute to clinical features in patients. However, the association of seropositive status with shorter duration of disease and more severe symptoms suggests a possible role of antibodies at onset in some patients and should be the focus of future studies. 相似文献